Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Light Coagulation

Light Coagulation

Light coagulation is a medical procedure that uses focused light energy to precisely target and coagulate, or fuse, specific tissue.
This technique is commonly used in ophthalmology, dermatology, and other medical fields to treat a variety of conditions, such as retinal tears, vascular lesions, and skin conditions.
The process involves directing a controlled beam of light, such as a laser, onto the targeted area, causing the tissue to heat up and fuse together.
Light coagulation is a minimally invasive procedure that can often be performed on an outpatient basis, with a relatively quick recovery time for the patient.
It is an important tool in the clinician's arsenal for diagnosing and treating a range of medical issues in a targeted and effeictive manner.

Most cited protocols related to «Light Coagulation»

1
Laser-Induced Retinal Lesions in Mice
Cited 16 times
Mice were anesthetized with a mixture of xylazine (6 mg/kg) and ketamine (100 mg/kg), and pupils were dilated with topical drops of Cyclomydril (Alcon Laboratories, Fort Worth, TX). Two minutes after pupil dilation, lubricating eye drops (Alcon Laboratories) were applied to the cornea. The fundus was viewed with an imaging camera, and laser photocoagulation was induced using the image-guided laser system (Micron IV, Phoenix Research Laboratories, Pleasanton, CA). The fundus image as well as the aiming beam can be observed on the monitor screen. Four laser burns at equal distance from the optic nerve were induced one by one in each eye by a green Argon laser pulse with a wavelength of 532 nm, a fixed diameter of 50 μm, duration of 70 ms, and varying power levels from 180 mW to 360 mW. If necessary, an orienting laser shot can also be generated approximately three times of the diameter of the optic nerve to help determine the relative positions of the lesions in an eye. After laser photocoagulation, the eyes were gently rinsed with sterile saline to remove the lubricating eye drops and treated with an antibiotic ointment, erythromycin (Fougera, Melville, NY). Mice were then placed on a pre-warmed warming plate at 35°C after the laser treatment until they awakened.
Gong Y., Li J., Sun Y., Fu Z., Liu C.H., Evans L., Tian K., Saba N., Fredrick T., Morss P., Chen J, & Smith L.E. (2015). Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice. PLoS ONE, 10(7), e0132643.
Publication 2015
Antibiotics Argon Ion Lasers Burns Cornea Erythromycin Eye Eye Drops Ketamine Light Coagulation Lubricant Eye Drops Mice, House Mydriasis Ointments Optic Nerve Pulse Rate Pupil Saline Solution Sterility, Reproductive Xylazine
2
Randomized Comparison of Diabetic Retinopathy Treatments
Cited 16 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Disease Progression Eligibility Determination Eye Light Coagulation Ranibizumab Triamcinolone Visual Acuity
3
Laser-Induced CNV in C57BL/6 Mice
Cited 11 times
CFB−/− mice on a C57BL/6 background were generously provided by V. Michael Holers (University of Colorado Health Science Center, Denver, CO). C57BL/6 mice were generated from breeding pairs (Harlan Laboratories, Indianapolis, IN). Animals were housed under a 12-hour light/12-hour dark cycle with access to food and water ad libitum.
For CNV lesions, 3-month-old mice were anesthetized (20 mg/kg xylazine, 80 mg/kg ketamine), and pupils were dilated (2.5% phenylephrine HCl and 1% atropine sulfate). Argon laser photocoagulation (532 nm, 100 μm spot size, 0.1 second duration, 100 mW) was used to generate four laser spots in each eye surrounding the optic nerve with the use of a handheld coverslip as a contact lens. Bubble formation at the laser spot indicated the rupture of Bruch membrane.17 (link)
For tail-vein injections, the vein was vasodilated by heat, a 25-gauge needle was inserted, and a 50 μL volume was injected (250 μg CR2-fH in PBS, molar equivalent of CR2 in PBS [113 μg], or PBS only). Dosing and treatment schedules are outlined in Results. All experiments were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the University Animal Care and Use Committee.
Rohrer B., Long Q., Coughlin B., Wilson R.B., Huang Y., Qiao F., Tang P.H., Kunchithapautham K., Gilkeson G.S, & Tomlinson S. (2009). A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-Related Macular Degeneration. Investigative ophthalmology & visual science, 50(7), 3056-3064.
Publication 2009
Animals Argon Ion Lasers Bruch Membrane Contact Lenses Exanthema Food Ketamine Light Coagulation Mice, House Mice, Inbred C57BL Molar Needles Optic Nerve Phenylephrine Hydrochloride Pupil Sulfate, Atropine Tail Treatment Protocols Veins Vision Xylazine
4
Quantifying CNV Vascular Leakage
Cited 10 times
FFA to determine leakage (not to determine lesion size) was performed with the retinal imaging microscope (Micron IV, Phoenix Research Laboratories) 6 days after laser photocoagulation. Mice were anesthetized, pupils dilated, and intraperitoneally injected with fluorescein AK-FLUOR (Akorn, Lake Forest, IL) at 5 μg/g body weight. Fluorescent fundus images were taken with the retinal imaging microscope at 5 and 10 minutes after fluorescein injection. The fluorescent intensity of CNV lesions was graded using ImageJ (National Institutes of Health, Bethesda, MD) by masked researchers [12 (link)], and the difference of fluorescent intensity between 5 and 10 minute images were recorded as an indicator of CNV vascular leakage.
Gong Y., Li J., Sun Y., Fu Z., Liu C.H., Evans L., Tian K., Saba N., Fredrick T., Morss P., Chen J, & Smith L.E. (2015). Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice. PLoS ONE, 10(7), e0132643.
Publication 2015
Blood Vessel Body Weight Fluorescein Forests Light Coagulation Microscopy Mus Pupil Retina
5
Cardiovascular Outcomes in Diabetes
Cited 9 times
The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal (including silent) myocardial infarction, or nonfatal stroke. Prespecified exploratory outcomes included an expanded composite cardiovascular outcome (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure), death from any cause, a composite renal and retinal microvascular outcome (nephropathy [defined as the new onset of macroalbuminuria or a doubling of the serum creatinine level and an eGFR of ≤45 ml per minute per 1.73 m2, the need for continuous renal-replacement therapy, or death from renal disease] and retinopathy [defined as the need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or the onset of diabetes-related blindness]), neoplasms, and pancreatitis — all of which were adjudicated in a blinded fashion by an external, independent event-adjudication committee. The definitions that were used for the clinical events and the members of the committee are listed in the Supplementary Appendix.
The glycated hemoglobin level was measured at randomization, at month 3, and then every 6 months thereafter. Other laboratory tests were performed at randomization, at months 6 and 12, and annually thereafter. Prespecified comparisons between groups were performed at 36 months, which was the last annual visit with laboratory testing that was prespecified for the entire trial population, given the minimum follow-up of 42 months.
Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., Nissen S.E., Pocock S., Poulter N.R., Ravn L.S., Steinberg W.M., Stockner M., Zinman B., Bergenstal R.M, & Buse J.B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 375(4), 311-322.
Publication 2016
Angina, Unstable Blindness Cardiovascular System Cerebrovascular Accident Committee Members Congestive Heart Failure Continuous Renal Replacement Therapy Creatinine Diabetes Mellitus EGFR protein, human Heart Hemoglobin, Glycosylated Hospitalization Kidney Kidney Diseases Light Coagulation Myocardial Infarction Neoplasms Pancreatitis PER1 protein, human Retina Retinal Diseases Serum Vitreous Hemorrhage

Most recents protocols related to «Light Coagulation»

1
Aqueous Flare Changes After Panretinal Photocoagulation in Diabetic Retinopathy
The records of 352 patients who underwent PRP due to PDR in one eye Department of Retina Beyoglu Eye Training and Research Hospital between January and March 2021 were reviewed retrospectively. Patients who underwent PRP in one eye but not in the other eye were included in the study. Patients who had previous ocular surgery, patients using steroids or other anti-inflammatory drugs, patients who received anti-VEGF therapy in the past month, patients with a history of ocular trauma/uveitis, and patients with vitreous hemorrhage, macular edema, tractional retinal detachment, and patients with HbA1c higher than 8.0 were excluded from the study. PRP applied eyes were taken as the study group and the other PRP-naive eyes were taken as the control group.
The study was carried out in accordance with the Declaration of Helsinki and was approved by the University of Health Sciences Hamidiye Scientific Research Ethics Committee with the decision number 13/2 on May 13, 2022. Informed consent was obtained from all patients in the study.
All patients underwent a full ophthalmologic examination before retinal photocoagulation. The best corrected visual acuity, IOP measured by Goldmann applanation tonometry, biomicroscopy, and dilated fundus examination findings were recorded. The other systemic/ocular diseases, surgeries, and drug use were questioned.
Retinal photocoagulation was performed with the pattern scan laser (PASCAL) system (PASCAL Synthesis, Topcon Medical Laser Systems, Santa Clara, CA) with a 200 micron spot size and an exposure time of 20–30 ms. The laser power was started with 200 mW and increased until a gray-white lesion was formed on the retina. 1000–1200 numbers of pulse were made in a single session. Any medication was not administered after PRP.
The laser flare meter (FC-700, Kowa Co. Ltd, Tokyo, Japan) was used to measure flare of aqueous humor. Measurements were performed by the same clinician. The mean of five consecutive reliable measurements was taken as the aqueous flare value. The values of flare meter were expressed as photon counts per millisecond (pc/ms).
Laser flare photometry and Goldmann applanation tonometry were both performed just before PRP and at the 1st and 24th h after PRP. At each visit, measurements were performed in both eyes consecutively and the other eye was accepted as the control eye.
“Statistical Package for the Social Sciences” version 20 software was used for statistical analysis. Continuous variables were reported as mean, standard deviation, and range. Categorical variables were expressed as absolute numbers and percentages. After evaluating the normality of the data with the Shapiro–Wilk test; the repeated measures analysis of variance (ANOVA) test with Greenhouse-Geisser correction was used to compare the values before and after retinal photocoagulation. If there was a significant difference with the repeated measures ANOVA test, Bonferroni correction was used to adjust of pairwise comparisons. Comparisons with the control eyes were made using an independent sample t-test. The correlation between variables was evaluated with the Pearson correlation coefficient. If p<0.05, the difference between values was considered statistically significant.
Atik B.K., Altan C., Pehlivanoglu S, & Ahmet S. (2023). Aqueous Flare and Intraocular Pressure in the Early Period Following Panretinal Photocoagulation in Patient with Proliferative Diabetic Retinopathy. Beyoglu Eye Journal, 8(1), 26-31.
Publication 2023
Anabolism Anti-Inflammatory Agents Aqueous Flare Edema, Macular Ethics Committees, Research Eye Eye Injuries Light Coagulation Operative Surgical Procedures Patients Pharmaceutical Preparations Photometry Pulse Rate Radionuclide Imaging Retina Retinal Detachment Slit Lamp Steroids Therapeutics Tonometry, Ocular Traction Uveitis Vascular Endothelial Growth Factors Vision Visual Acuity Vitreous Hemorrhage
2
Bevacizumab for Treatment-Naïve Unilateral CRVO
This study was a retrospective consecutive case series of patients diagnosed with treatment-naïve unilateral CRVO between January 2010 and September 2017 at the Hangil Eye Hospital. The inclusion criteria for this study were as follows: (1) symptomatic CRVO in which retinal hemorrhage and retinal edema involved the macula, (2) foveal thickness greater than 300 μm as measured by OCT at initial visits, and (3) macular edema treated with intravitreal bevacizumab. An intravitreal injection of bevacizumab was administered in the same manner as reported previously28 (link). All patients were treated using a pro-re-nata regimen. The diagnosis of CRVO was based on the findings from fundus examination and fluorescein angiography. CRVO with a non-perfusion area larger than 10 disc areas on fluorescein angiography was defined as ischemic CRVO. Visual acuity improvement of 2 lines or more in the CRVO eyes following treatment was defined as a functional responder.
The exclusion criteria of the study included patients with any coexisting ocular diseases, such as age-related macular degeneration, diabetic retinopathy, and uveitis, as well as eyes that had received focal/grid laser photocoagulation, pan-retinal photocoagulation, prior intravitreal injections (e.g., intravitreal corticosteroids, intravitreal anti-VEGF agents), or prior ocular surgery (except cataract surgery). Patients were also excluded if they had refractive disorders greater than ± 3D.
Patient charts were reviewed for the following data: age, sex, medical history (hypertension and diabetes mellitus), best-corrected visual acuity (BCVA), axial length (measured with the IOL master; Carl Zeiss Meditec, Dublin, California, USA), anti-VEGF injection dates, and number of intravitreal injections. BCVA was converted to the logarithm of the minimum angle of resolution (logMAR). The BCVA, IOP, and SFCT were compared between CRVO eyes and fellow eyes at each follow-up visit.
Hwang D.D, & Lee H.J. (2023). Long-term changes in the choroidal thickness in patients with unilateral central retinal vein occlusion. Scientific Reports, 13, 3711.
Publication 2023
Adrenal Cortex Hormones Age-Related Macular Degeneration Anti-Anxiety Agents Bevacizumab Cataract Extraction Diabetes Mellitus Diabetic Retinopathy Diagnosis Edema, Macular Eye Fluorescein Angiography High Blood Pressures Light Coagulation Macula Lutea N-acetyltryptophanamide Patients Perfusion Refractive Errors Retina Retinal Edema Retinal Hemorrhage Treatment Protocols Uveitis Vascular Endothelial Growth Factors Vision Visual Acuity
3
Laser-Induced Ocular Hypertension Model

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Adrenal Cortex Hormones Anesthesia Antibiotics Aqueous Humor Betamethasone Chambers, Anterior Eye Eye Drops Infection Inflammation Injections, Intraperitoneal Ketamine Light Coagulation Mus Ocular Hypertension Ointments Pharmaceutical Preparations Phenylephrine Hydrochloride Pupil Tropicamide Xylazine
4
Retinal Ganglion Cell Survival Evaluation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Administration, Ophthalmic Eye Light Coagulation Microscopy, Fluorescence Mus Optic Disk paraform Pharmaceutical Preparations Phosphates Pressure Retina Saline Solution
5
Laser Photocoagulation for Diabetic Macular Edema
This prospective interventional study was approved by the Institutional Ethics Committee of the Graduate School of Medicine and the Faculty of Medicine at the University of Tokyo (#11986). Written informed consent was obtained from all patients. The procedures were conducted in accordance with the tenets of the Declaration of Helsinki.
Consecutive patients were recruited from the Department of Ophthalmology at the University of Tokyo Hospital between March 2019 and June 2020. The inclusion criteria were clinically significant DME with apparent leaking MAs and eligibility for FA. Each patient was informed about the treatment options, including anti-VEGF and steroid therapies, and the risks and benefits of laser photocoagulation. Patients who were reluctant to use anti-VEGF therapy for economic or psychological reasons, had recurrent DME despite previous treatments, and were eligible for laser photocoagulation treatment were recruited to the study. All enrolled patients underwent comprehensive ophthalmologic examinations. The best-corrected visual acuity (BCVA) was measured at baseline before laser photocoagulation and at the 1- and 3-month follow-ups. The major exclusion criteria were previous pars plana vitrectomy, intraocular surgery in the last 6 months, treatment for macular edema in the last 6 months, significant media opacities, and a diagnosis or history of any ocular disease that might influence the study results, including age-related macular degeneration, inflammatory eye disease, neurodegenerative disease, and vitreomacular traction syndrome.
Ikegami Y., Shiraya T., Araki F., Ueta T., Toyama T., Yanagita T., Numaga J., Shoji N, & Kato S. (2023). Microperimetric analysis of diabetic macular edema after navigated direct photocoagulation with short-pulse laser for microaneurysms. International Journal of Retina and Vitreous, 9, 12.
Publication 2023
Age-Related Macular Degeneration Diagnosis Edema, Macular Eligibility Determination Eye Disorders Faculty, Medical Inflammation Institutional Ethics Committees Light Coagulation Neurodegenerative Disorders Operative Surgical Procedures Patients Physical Examination Planum Poly(ADP-ribose) Polymerases Steroids Syndrome Traction Vascular Endothelial Growth Factors Vision Visual Acuity Vitrectomy

Top products related to «Light Coagulation»

1
Micron 4 by Phoenix Pharmaceuticals
Sourced in United States
The Micron IV is a compact and versatile laboratory equipment designed for a range of scientific applications. It features a high-precision fluid delivery system capable of accurately measuring and dispensing small volumes of liquids. The Micron IV is suitable for a variety of tasks, including sample preparation, reagent addition, and automated liquid handling.
2
Constellation vision system by Alcon
Sourced in United States, Germany
The Constellation Vision System is a surgical platform designed for ophthalmic procedures. It provides advanced control and precision for the surgeon during operations. The system integrates multiple components to support the surgical workflow.
3
Tropicamide by Alcon
Sourced in United States, Spain, Switzerland, Denmark, Australia, Belgium
Tropicamide is a synthetic chemical compound used in ophthalmic applications. It is a pupil dilator that temporarily enlarges the pupil of the eye. Tropicamide is commonly used in eye examinations and diagnostic procedures to facilitate the examination of the inside of the eye.
4
Spectralis oct by Heidelberg Engineering
Sourced in Germany, United States, United Kingdom, Japan
The Spectralis OCT is a high-resolution optical coherence tomography (OCT) imaging system designed for clinical use. It provides detailed, cross-sectional images of the eye's internal structures, enabling healthcare professionals to diagnose and monitor a variety of ocular conditions.
5
Rompun by Bayer
Sourced in Germany, France, United States, United Kingdom, Canada, Italy, Brazil, Belgium, Cameroon, Switzerland, Spain, Australia, Ireland, Sweden, Portugal, Netherlands, Austria, Denmark, New Zealand
Rompun is a veterinary drug used as a sedative and analgesic for animals. It contains the active ingredient xylazine hydrochloride. Rompun is designed to induce a state of sedation and pain relief in animals during medical procedures or transportation.
6
Spectralis by Heidelberg Engineering
Sourced in Germany, United States, United Kingdom, Japan, Switzerland, Ireland
The Spectralis is an optical coherence tomography (OCT) imaging device developed by Heidelberg Engineering. It captures high-resolution, cross-sectional images of the retina and optic nerve using near-infrared light. The Spectralis provides detailed structural information about the eye, which can aid in the diagnosis and management of various eye conditions.
7
Tropicamide by Santen
Sourced in Japan, China, Belgium, Germany
Tropicamide is a mydriatic and cycloplegic agent used in ophthalmic examinations and procedures. It is a pharmaceutical product designed to temporarily dilate the pupil and temporarily paralyze the ciliary muscle, which controls the eye's focusing ability.
8
Zoletil by Virbac
Sourced in France, United States, Italy, Australia, Germany, China, Thailand, Cameroon, United Kingdom, Netherlands, New Zealand
Zoletil is a general anesthetic and analgesic used in veterinary medicine. It is a combination of two active compounds, tiletamine and zolazepam, that work together to induce a state of deep sedation and pain relief in animals. The product is administered by injection and is commonly used for a variety of veterinary procedures, including surgery, diagnostic imaging, and minor treatments. Zoletil is intended for use under the supervision of licensed veterinary professionals.
9
Mydrin p by Santen
Sourced in Japan, Germany
Mydrin-P is a laboratory product used for ophthalmic purposes. It functions as a mydriatic agent, intended to dilate the pupil.
10
Xylazine by Bayer
Sourced in Germany, France, Japan, United States, Brazil, Spain, Canada, Switzerland, Cameroon, Australia, United Kingdom
Xylazine is a pharmaceutical product used as a sedative and analgesic in veterinary medicine. It is a central alpha-2 adrenergic agonist that produces a calming effect and pain relief in animals. Xylazine is used to facilitate handling, examination, and minor surgical procedures in various animal species.

More about "Light Coagulation"

Light Coagulation: A Versatile Medical Procedure for Targeted Tissue Fusion.
Also known as laser coagulation or photocoagulation, this minimally invasive technique utilizes focused light energy to precisely treat a variety of conditions in fields like ophthalmology, dermatology, and beyond.
From retinal tears to vascular lesions, skin conditions, and more, light coagulation offers clinicians an effective diagnostic and treatment option with a quick recovery time for patients.
Key Subtopics and Related Terms: - Laser Coagulation: The use of laser light to induce tissue coagulation and fusion. - Photocoagulation: A broader term encompassing various light-based coagulation methods. - Ophthalmic Applications: Treating retinal tears, diabetic retinopathy, and other eye conditions using Micron IV, Constellation Vision System, Spectralis OCT, etc. - Dermatological Uses: Addressing vascular lesions, skin tags, and other skin issues through light-based coagulation. - Anesthesia Considerations: Mydrin-P, Zoletil, Xylazine, and Rompun may be used to facilitate light coagulation procedures. - Research Optimization: Platforms like PubCompare.ai can enhance light coagulation research by identifying optimal protocols and products from published literature, preprints, and patents.
Discover the versatility and precision of light coagulation in modern medical practice, and explore the cutting-edge tools and techniques driving advancements in this field.